InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
57,097.98
(
-2.06%
)
Post# of 108192
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

BarrellofHay

Send PM Follow Ignore
Followers 5
Posts 784
Boards Moderated 0
Alias Born 07/19/2006

BarrellofHay

Re: Julius_Kelp post# 47623

Thursday, 12/28/2017 10:49:21 PM

Thursday, December 28, 2017 10:49:21 PM

Post# of 108192
Thanks for the link on other phase 2 anal trials.

http://www.hematologyandoncology.net/files/2017/12/ho1217JohnsonEng-1.pdf

Looks like Nivolumab had an Orr of 24% compared to 3.5% for adxs. This poster released at same time that shares dropped from 7.5. Released on the 8th of September. This is not A good result compared to Nivolumab and is likely why study cancelled. Unless there were differences in the patients but I think I am comparing correctly. But so hard for the layman to be sure it’s not apples to oranges. Anyone?
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent ADXS News
More ADXS News
InvestorsHub NewsWire

Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM

Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM

EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM

BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM

NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM

Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM

Start posting your company's news
Only $200 per official company press release!